- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00159991
Copenhagen Arterial Revascularization Randomized Patency and Outcome Trial (CARRPO)
Arterial Revascularization for Coronary Bypass Surgery: A Randomized Trial Comparing the Outcome After Using LIMA + Vein Grafts Versus Total Arterial Revascularization With LIMA + RIMA + Radial Artery Grafts
Study Overview
Status
Intervention / Treatment
Detailed Description
I: Background
There is a remarkable lack of randomized studies concerning the potential benefit of using arterial grafts for coronary revascularization. Numerous observational reports consistently confirm, that the use of a LIMA-LAD grafts is not associated with increased peroperative mortality or morbidity and will result in an approximately 10% improved survival at 10 years postoperatively.
The average patency for LIMA-LAD grafts is 80%-85% after 10 years. 50% of the vein grafts are occluded. LIMA-LAD grafting reduces the risk of of late myocardial infarction, other cardiac events and reoperation, however the effect on recurrent angina or need of antianginal medication is less certain.
The question, whether bilateral IMA grafting has long term benefits compared to single IMA grafts is controversial. Numerous observational retrospective studies fail to demonstrate convincingly, that bilateral IMA grafting reduces long term mortality and improves the frequency of late cardiac events and recurrent angina, but these data are difficult to compare due to selection bias. It is not quite clear, if a minimal benefit represents a true difference in outcome, or if two different populations are compared.
Whether an increased degree of arterial revascularization, including radial artery (RA) and IMA grafts, will result in an improved long term survival, reduced risk for recurrent angina, reinfarction, antianginal medication and improved quality of life, is unclear.
A randomized trial has not yet been performed and current observational 5 year follow-up data are promising, but cannot document an anticipated benefit from a more stringent scientific point of view.
II: Hypothesis
Coronary bypass grafting with the use of LIMA + RIMA + RA (total arterial revascularization) vs. LIMA + saphenous vein grafts will result in equal peroperative mortality and morbidity rates and improve long term outcome in terms of improved patency rates, reduced risk of recurrent angina, infarction and other cardiac events, reduced need for antianginal medication, improved functional status and possibly improved long term survival.
III: Aim of the study
Prospective randomized trial comparing coronary bypass grafting with the use of LIMA + RIMA + RA vs. LIMA + saphenous vein grafts in patients with 2 or 3 vessel disease (more than 1 graft anticipated) with respect to:
- Graft patency rates at 1, 5 and 10 years postoperatively
- Cardiac event free survival 1, 5 and 10 years postoperatively (risk of hospital readmission due to infarction, suspicion of infarction, unstable angina, arrythmias, heart insufficiency, need for renewed angiography, angioplasty, redo surgery)
- Peroperative mortality and morbidity
- Risk of recurrent angina and need for antianginal medication 1, 5 and 10 years postoperatively
- Data on functional status and social rehabilitation at clinical controls 3 months, 1, 5 and 10 years postoperatively
IV: Design & methods
Design
Prospective randomized trial. Patients will be randomized into 2 groups:
Group A: Arterial revascularization with LIMA + RIMA + RA.
Group B: LIMA and saphenous vein grafts are used as graft material.
Inclusion criteria
- Patients with 2 or 3 vessel coronary artery disease, where more than 1 coronary bypass graft is anticipated.
- Elective or subacute operation (unstable AP with surgery within a few days)
- Inclusion is independent of ventricular function, recent MI, degree and type of coronary lesions and secondary risk factors as diabetes, hyperlipidemia, hypertension, lung function, chronic obstructive lung disease, peripheral atherosclerotic disease, kidney function, earlier cerebrovascular disease.
- Age: < 70 years.
- Sufficient collateral blood supply to the hand by the ulnar artery, evaluated by the Allen test.
- Patients must be able to give informed consent.
Exclusion criteria
- Concurrent malignant disease with expected survival of < 5 years.
- Unsuitable saphenous vein grafts evaluated preoperatively.
- Unsuitable saphenous vein grafts with a diameter > 6mm evaluated peroperatively.
- Acute operation (unstable hemodynamics in terms of need of inotropic support, ongoing MI with dynamic ECG changes, cardiogenic shock).
- Concommitant operation for valve disease or other forms of heart surgery.
- Redo operations.
Surgery, anaesthesia and postoperative care
Surgery, anaesthesia and postoperative care are performed according to current guidelines at our institution.
Endpoints and follow-up
The study is designed with respect to two primary endpoints:
- Distal anastomotic patency rates at 1, 5 and 10 years postoperatively
- Cardiac event free survival 1, 5 and 10 years postoperatively (Cardiac event free survival is defined as survival without readmission due to infarction, suspicion of infarction, unstable angina, arrythmias, heart insufficiency, need for renewed angiography, angioplasty, redo surgery)
Secondary endpoints:
- Peroperative mortality and morbidity (frequency of peroperative/ postoperative infarction, arrythmias, use of IABP, inotropic support, pulmonary, renal and cerebral complications, length of stay in the ICU, etc. according to registration schemes).
- Risk of recurrent angina and need for antianginal medication 1, 5 and 10 years postoperatively
- Data on functional status and social rehabilitation at clinical controls 3 months, 1, 5 and 10 years postoperatively
According to these endpoints the follow-up is planned as:
- 3 month clinical control at referring hospitals
- 1 year control including angiography, which can be performed on an outpatient basis.
- 5 year control including conventional angiography and computed tomography angiography.
- 10 year control including computed tomography angiography, which can be performed on an outpatient basis.
- Statistics
Sample size is calculated with respect to the primary endpoint graft patency at 1 and 5 years. A difference of 10-15% of patency in favour of the radial artery as bypass graft is regarded as clinically relevant. Observational data on radial artery patency indicate patency rates of 90-95% at 1 year and 85% at 5 years, while saphenous vein graft patency is 80-90% at 1 year and 60-70% at 5 years.
To detect such a difference (15% improved patency for RA grafts, 85% vs 70%) with a 90% probability (type 2 error 0.10) and a significance level of 0.05, the sample size for each group would be n=150.
A 15% difference in patency rates at 5 years is in our opinion an assumption that probably overestimates the vein graft patency, which means, that a sample size of 150 patients in each group should guarantee with a high probability a statistically significant outcome.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Department of cardiothoracic surgery, Rigshospitalet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with 2 or 3 vessel coronary artery disease, where more than 1 coronary bypass graft is anticipated.
- Elective or subacute operation (unstable AP with surgery within a few days)
- Inclusion is independent of ventricular function, recent MI, degree and type of coronary lesions and secondary risk factors as diabetes, hyperlipidemia, hypertension, lung function, chronic obstructive lung disease, peripheral atherosclerotic disease, kidney function, earlier cerebrovascular disease.
- Age: < 70 years.
- Sufficient collateral blood supply to the hand by the ulnar artery, evaluated by the Allen test.
- Patients must be able to give informed consent.
Exclusion Criteria:
- Concurrent malignant disease with expected survival of < 5 years.
- Unsuitable saphenous vein grafts evaluated preoperatively.
- Unsuitable saphenous vein grafts with a diameter > 6mm evaluated preoperatively.
- Acute operation (unstable hemodynamics in terms of need of inotropic support, ongoing MI with dynamic ECG changes, cardiogenic shock).
- Concommitant operation for valve disease or other forms of heart surgery. Redo operations.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
Total arterial revascularization
|
Coronary artery bypass grafting using LIMA and RIMA and/or radial artery grafts
Other Names:
|
Active Comparator: B
Conventional revascularization
|
Coronary artery bypass grafting using LIMA and saphenous vein grafts
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Angiographic distal anastomotic patency rates
Time Frame: 1, 5 and 10 years postoperatively
|
1, 5 and 10 years postoperatively
|
Cardiac event free survival
Time Frame: 1, 5 and 10 years postoperatively
|
1, 5 and 10 years postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Peroperative mortality
Time Frame: Until 3 months postoperatively
|
Until 3 months postoperatively
|
Postoperative morbidity (frequency of peroperative/ postoperative infarction, arrythmias, use of IABP, inotropic support, pulmonary, renal and cerebral complications, length of stay in the ICU, etc. according to registration schemes).
Time Frame: 3 months postoperatively
|
3 months postoperatively
|
Risk of recurrent angina and need for antianginal medication
Time Frame: 1, 5 and 10 years postoperatively
|
1, 5 and 10 years postoperatively
|
Data on functional status and social rehabilitation at clinical controls
Time Frame: 3 months, 1, 5 and 10 years postoperatively
|
3 months, 1, 5 and 10 years postoperatively
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sune Damgaard, MD, Dept. of Cardiothoracic Surgery, Rigshospitalet, Copenhagen
- Study Director: Daniel A Steinbrüchel, Professor, Dept. of Cardiothoracic Surgery, Rigshospitalet, Copenhagen
- Study Chair: Jens T Lund, Consultant, Dept. of Cardiothoracic Surgery, Rigshospitalet, Copenhagen
- Study Chair: Henning Kelbæk, Consultant, Cardiac Cath. Lab., Rigshospitalet, Copenhagen
- Study Chair: Jan K Madsen, Consultant, Dept. of Cardiology, Gentofte County Hospital, Copenhagen
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 961502837
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angina Pectoris
-
University Hospital, AntwerpRecruitingAngina Pectoris, Variant | Angina Pectoris; Spasm-Induced | Angina Pectoris With Normal Coronary ArteriogramBelgium
-
The People's Hospital of Liaoning ProvinceUnknownStable Angina Pectoris | Unstable Angina PectorisChina
-
Society for Advancement of Coronary Intervention...UnknownStable Angina Pectoris | Unstable Angina PectorisJapan
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentNot yet recruitingAngina Pectoris; Angiospastic
-
Region Örebro CountyBiosensors InternationalWithdrawnStable Angina Pectoris | Unstable Angina Pectoris | Myocardial Infacrtion
-
Atlantic Health SystemMallinckrodtTerminatedStable Angina Pectoris | Unstable Angina Pectoris | Silent IschemiaUnited States
-
Zhejiang Chinese Medical UniversityThe Third Affiliated hospital of Zhejiang Chinese Medical University; The First...UnknownChronic Stable Angina PectorisChina
-
Zhejiang Chinese Medical UniversityThe Third Affiliated hospital of Zhejiang Chinese Medical University; The First...UnknownChronic Stable Angina PectorisChina
-
Zhejiang Chinese Medical UniversityThe First Affiliated Hospital of Zhejiang Chinese Medical UniversityUnknownChronic Stable Angina PectorisChina
-
Zhejiang Chinese Medical UniversityThe Third Affiliated hospital of Zhejiang Chinese Medical University; The First...Unknown
Clinical Trials on Total arterial revascularization
-
Liverpool University Hospitals NHS Foundation TrustCompletedPeripheral Arterial DiseaseUnited Kingdom
-
Vascular Solutions LLCBright Research Partners; TeleflexCompletedIschemic Heart Disease | Chronic Total Occlusion | Chronic Total Occlusion of Coronary ArteryUnited States
-
University Hospital ErlangenCompletedEnd-stage Renal Disease | Critical Limb IschemiaGermany
-
Rigshospitalet, DenmarkUniversitaire Ziekenhuizen KU Leuven; UMC Utrecht; Copenhagen Trial Unit, Center...Not yet recruitingCoronary Artery Disease
-
ECRI bvSiemens Healthineers AG; Pie Medical ImagingRecruitingCoronary Artery DiseaseGermany, Ireland, Italy, Netherlands, Spain, United Kingdom, France
-
Silk Road MedicalCompletedCarotid Artery Plaque | Carotid Stenosis | Carotid Artery Diseases | Carotid Atherosclerosis | Carotid DiseaseUnited States, Spain
-
Consorzio Futuro in RicercaActive, not recruitingMyocardial InfarctionSpain, Italy, Poland
-
Federal State Budgetary Institution National Medical...Kemerovo Cardiology Center, Tarasov Roman Sergeevich; Tomsk National Research...RecruitingCoronary Syndrome, Acute, Non-ST Elevation, High Risk PatientsRussian Federation
-
Samsung Medical CenterChonnam National UniversityActive, not recruitingCancer | Acute Myocardial InfarctionKorea, Republic of
-
Silk Road MedicalRecruitingCarotid Artery DiseasesUnited States